当前位置: X-MOL 学术ACS Pharmacol. Transl. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Physiologically Based Pharmacokinetic/Pharmacodynamic Model for the Treatment of Dengue Infections Applied to the Broad Spectrum Antiviral Soraphen A
ACS Pharmacology & Translational Science ( IF 4.9 ) Pub Date : 2021-08-30 , DOI: 10.1021/acsptsci.1c00078
Katharina Rox 1, 2, 3 , Maxi Heyner 4, 5 , Jana Krull 1 , Kirsten Harmrolfs 6 , Valtteri Rinne 7 , Juho Hokkanen 7 , Gemma Perez Vilaro 8 , Juana Díez 8 , Rolf Müller 2, 6 , Andrea Kröger 4, 5 , Yuichi Sugiyama 3 , Mark Brönstrup 1, 2
Affiliation  

While a drug treatment is unavailable, the global incidence of Dengue virus (DENV) infections and its associated severe manifestations continues to rise. We report the construction of the first physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model that predicts viremia levels in relevant target organs based on preclinical data with the broad spectrum antiviral soraphen A (SorA), an inhibitor of the host cell target acetyl-CoA-carboxylase. SorA was highly effective against DENV in vitro (EC50 = 4.7 nM) and showed in vivo efficacy by inducing a significant reduction of viral load in the spleen and liver of IFNAR–/– mice infected with DENV-2. PBPK/PD predictions for SorA matched well with the experimental infection data. Transfer to a human PBPK/PD model for DENV to mimic a clinical scenario predicted a reduction in viremia by more than one log10 unit for an intravenous infusion regimen of SorA. The PBPK/PD model is applicable to any DENV drug lead and, thus, represents a valuable tool to accelerate and facilitate DENV drug discovery and development.

中文翻译:

用于治疗登革热感染的生理学药代动力学/药效学模型应用于广谱抗病毒药物 Soraphen A

虽然无法获得药物治疗,但登革热病毒 (DENV) 感染及其相关严重表现的全球发病率继续上升。我们报告了第一个基于生理学的药代动力学/药效学 (PBPK/PD) 模型的构建,该模型基于广谱抗病毒药物 soraphen A (SorA) 的临床前数据预测相关靶器官中的病毒血症水平,SorA 是宿主细胞靶乙酰-的抑制剂。 CoA-羧化酶。SorA在体外对 DENV 非常有效(EC 50 = 4.7 nM),并通过诱导 IFNAR 在脾脏和肝脏中的病毒载量显着降低而显示出体内功效–/–感染 DENV-2 的小鼠。SorA 的 PBPK/PD 预测与实验感染数据非常吻合。转移到 DENV 的人类 PBPK/PD 模型以模拟临床情况,预测SorA 静脉输注方案的病毒血症减少超过一个 log 10单位。PBPK/PD 模型适用于任何 DENV 药物先导,因此是加速和促进 DENV 药物发现和开发的宝贵工具。
更新日期:2021-10-08
down
wechat
bug